Suspended

Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)

+ drug coated balloon inflation (Cotavance, Medrad Inc.)

+ uncoated balloon (e.g. Admiral, Medtronic)

Device
Who is being recruted

Arterial Occlusive Diseases+4

+ Arteriosclerosis

+ Cardiovascular Diseases

Over 18 Years
+33 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Placebo-ControlledPhase 2 & 3
Interventional
Study Start: January 2012
See protocol details

Summary

Principal SponsorProf. Dr. med. Gunnar Tepe
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 1, 2012

Actual date on which the first participant was enrolled.

In stent restenosis in peripheral artery disease (superficial and popliteal artery) either treated with uncoated or paclitaxel coated balloons.

Official TitleCotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study
NCT01594684
Principal SponsorProf. Dr. med. Gunnar Tepe
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

112 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Arterial Occlusive DiseasesArteriosclerosisCardiovascular DiseasesVascular DiseasesPeripheral Vascular DiseasesAtherosclerosisPeripheral Arterial Disease

Criteria

10 inclusion criteria required to participate
In-stent restenosis or re-occlusion at the target lesion due to an interventional treatment > 3 months prior to enrollment.

Has evidence of ≥ 70% stenosis or occlusion in the SFA and/or popliteal confirmed by angiography that is 3-27 cm long.

Reference vessel diameter of 3 to 7 mm (reference vessel diameter = normal vessel diameter 1 cm proximal of the index lesion)

Patients (men and women) with PAD disease category 2 to 5 according to Rutherford classification.

Show More Criteria

23 exclusion criteria prevent from participating
Patients with more than two lesions in the target vessel requiring treatment (if the distance between two lesions is less than 2 cm, the lesions should be counted as one lesion). The second lesion should also be treated with either coated or uncoated balloons (according to the randomization)

Guidewire cannot cross lesion and/or an intentional subintimal approach in the stented lesion is required.

Patients with stent fractures grade 2-4.

Inflow lesion (proximal to the study lesion) with flow limitation not being successfully treated prior to treatment of the study lesion.

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator
treatment with drug eltuing balloon

Group II

Placebo
treatment with uncoated balloon

Group III

Active Comparator
if treatment fails 30 days or later

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 6 locations

Recruiting

Herzzentrum Bad Krozingen

Bad Krozingen, GermanyOpen Herzzentrum Bad Krozingen in Google Maps
Recruiting

Tepe

Rosenheim, Germany
Recruiting

Uniklinik Tübingen

Tübingen, Germany
Recruiting

Jüdisches Krankenhaus

Berlin, Germany
Suspended6 Study Centers